Literature DB >> 7737561

Helicobacter pylori eradication in the African setting, with special reference to reinfection and duodenal ulcer recurrence.

J A Louw1, W Lucke, K Jaskiewicz, A J Lastovica, T A Winter, I N Marks.   

Abstract

The aim of this study was to determine the effect of Helicobacter pylori eradication on the natural history of duodenal ulcer disease, and to determine the incidence of reinfection in adult patients where H pylori had been eradicated in a community with a high prevalence of the infection. An investigator blinded study, with 24 month endoscopic follow up, in subjects where H pylori had been eradicated, and similarly treated subjects where it had not been eradicated was conducted at a tertiary referral hospital. The patients consisted of a volunteer sample of 48 patients with endoscopically proved active duodenal ulcer disease. Duodenal ulcers were healed with omeprazole, 20 mg/day. After endoscopically confirmed healing, patients were treated with either one (17 patients) or two weeks (31 patients) of 'triple therapy'. H pylori status (urease reaction, histological tests, and culture of antral biopsy specimens) was determined at entry, four weeks after the finish of triple therapy and six, 12, and 24 months after this, or whenever an endoscopically proved recurrent duodenal ulcer was found. The main outcome measures were the recurrence of duodenal ulceration, over 24 months in the eradicated and non-eradicated groups and the incidence of reinfection by H pylori in the eradicated group during this follow up period. Five patients in the eradicated group experienced a duodenal ulcer relapse, of which only three were unexplained (1 = reinfected, 1 = gastrinoma). Fifteen of 21 patients in the non-eradicated group relapsed over the same period (p < 0.001). Only two of 27 patients in the eradicated group were reinfected during the 24 month follow up period. It is concluded that H pylori eradication is an effective treatment strategy for the longterm treatment of duodenal ulcer disease, even in the high prevalence, African setting. Reinfection is uncommon.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7737561      PMCID: PMC1382494          DOI: 10.1136/gut.36.4.544

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.

Authors:  B J Marshall; C S Goodwin; J R Warren; R Murray; E D Blincow; S J Blackbourn; M Phillips; T E Waters; C R Sanderson
Journal:  Lancet       Date:  1988 Dec 24-31       Impact factor: 79.321

2.  Patient-to-patient transmission of Campylobacter pylori infection by fiberoptic gastroduodenoscopy and biopsy.

Authors:  W Langenberg; E A Rauws; J H Oudbier; G N Tytgat
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

3.  Attempt to fulfil Koch's postulates for pyloric Campylobacter.

Authors:  B J Marshall; J A Armstrong; D B McGechie; R J Glancy
Journal:  Med J Aust       Date:  1985-04-15       Impact factor: 7.738

4.  One-minute endoscopy room test for Campylobacter pylori.

Authors:  A S Arvind; R S Cook; S Tabaqchali; M J Farthing
Journal:  Lancet       Date:  1988-03-26       Impact factor: 79.321

5.  Evidence for the occurrence of the same strain of Campylobacter pylori in the stomach and dental plaque.

Authors:  B Shames; S Krajden; M Fuksa; C Babida; J L Penner
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

6.  Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection: implications for treatment of patients with duodenal ulcer disease.

Authors:  G D Bell; K U Powell; S M Burridge; G Harrison; B Rameh; J Weil; P W Gant; P H Jones; J E Trowell
Journal:  Q J Med       Date:  1993-06

7.  Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study.

Authors:  J G Coghlan; D Gilligan; H Humphries; D McKenna; C Dooley; E Sweeney; C Keane; C O'Morain
Journal:  Lancet       Date:  1987-11-14       Impact factor: 79.321

8.  Cure of duodenal ulcer after eradication of Helicobacter pylori.

Authors:  L L George; T J Borody; P Andrews; M Devine; D Moore-Jones; M Walton; S Brandl
Journal:  Med J Aust       Date:  1990-08-06       Impact factor: 7.738

9.  Cure of duodenal ulcer associated with eradication of Helicobacter pylori.

Authors:  E A Rauws; G N Tytgat
Journal:  Lancet       Date:  1990-05-26       Impact factor: 79.321

10.  Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication.

Authors:  T J Borody; P Cole; S Noonan; A Morgan; J Lenne; L Hyland; S Brandl; E G Borody; L L George
Journal:  Med J Aust       Date:  1989-10-16       Impact factor: 7.738

View more
  9 in total

Review 1.  Precise role of H pylori in duodenal ulceration.

Authors:  Michael Hobsley; Frank I Tovey; John Holton
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

Review 2.  Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes.

Authors:  H X Xia; N J Talley; C T Keane; C A O'Morain
Journal:  Dig Dis Sci       Date:  1997-09       Impact factor: 3.199

3.  High seroprevalence of IgG against Helicobacter pylori among endoscopists in Taiwan.

Authors:  Y C Su; W M Wang; L T Chen; W Chiang; C Y Chen; S N Lu; C M Jan
Journal:  Dig Dis Sci       Date:  1996-08       Impact factor: 3.199

4.  Cost effectiveness of Helicobacter pylori eradication therapies in patients with duodenal ulcer. An analysis of triple therapy versus two dual therapy alternatives.

Authors:  G R Tennvall; A Norinder; B Ohlin
Journal:  Pharmacoeconomics       Date:  1999-09       Impact factor: 4.981

Review 5.  A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy.

Authors:  U Peitz; A Hackelsberger; P Malfertheiner
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

Review 6.  Optimal therapy for Helicobacter pylori infections.

Authors:  Emiko Rimbara; Lori A Fischbach; David Y Graham
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 46.802

7.  Heterogeneity in the Helicobacter pylori vacA and cagA genes: association with gastroduodenal disease in South Africa?

Authors:  M Kidd; A J Lastovica; J C Atherton; J A Louw
Journal:  Gut       Date:  1999-10       Impact factor: 23.059

8.  Reinfection after successful eradication of Helicobacter pylori in three different populations in Alaska.

Authors:  M G Bruce; D L Bruden; J M Morris; A L Reasonover; F Sacco; D Hurlburt; T W Hennessy; J Gove; A Parkinson; G Sahagun; P Davis; J Klejka; B J McMahon
Journal:  Epidemiol Infect       Date:  2014-07-28       Impact factor: 4.434

Review 9.  Helicobacter pylori: therapeutic targets.

Authors:  J A Louw; I N Marks
Journal:  Yale J Biol Med       Date:  1998 Mar-Apr
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.